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Clinical studies with recombinant T N F did not sustain the great hope as 
an anticancer agent that was placed on T N F . This hope was based on the 
early toxin studies by Coley et al. [1] in which tumor regression and necrosis 
was probably conferred by endogenous T N F [2]. Several explanations could 
account for this discrepancy in activity of exogenous versus endogenous 
T N F . For example, the amount and the localization of applied versus 
induced T N F and the combination with other cytokines might determine the 
antitumor activity. Today, T N F can no longer be regarded to be solely a 
tumor cytotoxic or cytostatic agent. It is now generally accepted that it exerts 
a multitude of effects on many different cell types and that it can act as an 
important immunomodulator [3]. Therefore, these considerations raise the 
question whether tumor cells can induce T N F production and what role such 
endogenous tumor-induced T N F might play for the pathophysiology of 
human Cancer. 
Material and Methods 
Cell cultures: Culture methods of tumor cells and isolation procedures for human 
peripheral monocytes have been described recently [4]. The cell lines used in this study 
were K562, a proerythromyeloid cell line; Jurkat, a T cell line; CFS-1, a methylcholanth-
rene-induced fibrosarcoma cell line of C3H mouse origin; Lewis lung Carcinoma cells 
kindly provided by H. Osswald, Heidelberg; ESb, a T cell lymphoma of DBA/2 mouse 
origin kindly provided by V. Schirrmacher, Heidelberg. 
Tumor models: For tumor induction 106 CFS-1 cells or ESb cells were implanted i.d. 
on the flanks of C3H or DBA/2 mice, respectively. Lewis lung Carcinoma cells were 
passaged from lung metastases i.m. into B6/D2 mice. 

TNF assays: L929 bioassay and TNF ELISA were performed as described recently 
Membrane preparation and chromatography: The methods for membrane prepara-
tion and chromatography have been described recently [4]. HPLC gel permeation 
chromatography was performed on a Beckmann System Gold System with a Beckmann 
TSK 3000 SW column. 
Northern blot and in situ hybridization procedures: RNA extraction and hybridiza-
tions were performed as described recently [4, 5]. cDNA and RNA probes used were: a 
750-bp EcoKl fragment of the coding region of human TNF cDNA; a 460-bp human IL-1 
EcoRl-BamHl DNA fragment (p3 IL-la) and a 530-bp human IL-lß BamHl-Ndel DNA 
fragment (pl 1 IL-lß) of the coding region, respectively, kindly provided by U. Gubler, 
Hoffmann-La Roche, Nutley, N.J.; a 560-bp Saä-EcoRl fragment of human ß-actin 
cDNA; a TNF RNA probe consisting of a 750-bp EcoKl fragment of the coding region was 
synthesized with T7 RNA Polymerase in the presence of 3 5 S-UTP. 
Results 
TNF Production Induced by Tumor Cells in vitro 
Several reports describe the correlation of monocyte/macrophage activa-
tion and T N F production in a host with tumor bürden [6-9]. We therefore 
investigated in vitro whether tumor cells could stimulate human peripheral 
blood monocytes from healthy donors to synthesize T N F and IL-1 [4]. The 
human tumor cell lines K562, a proerythromyeloid cell line, and Jurkat, a T 
cell line, were used to stimulate the adherent fraction of freshly isolated 
peripheral blood mononuclear leukocytes. Cultivation of Jurkat cells with 
monocytes for 16 h led to the release of soluble T N F which was measured by 
the sensitive bioassay as well as by the TNF-specific ELISA. K562 did not 
induce the release of measurable amounts of soluble TNF. In addition, a 17-
k D T N F protein biosynthetically labeled with radioactive leucine was im-
munoprecipitated from the supernatant of Jurkat cells stimulated with 
monocytes, whereas Western blot analysis of monocytes stimulated with 
both Jurkat and K562 showed the appearance of 26 kD cell-associated T N F 
protein. Both cell lines, K562 and Jurkat, induced the expression of T N F 
m R N A and IL-1 mRNA in the monocytes (fig. la, b). This indicated that 
both tumor cell lines activated the monocytes and induced biosynthesis of 
T N F . 
The activating agent of the tumor cells was found to be associated with 
the outer cell membrane. Nonadherent peripheral blood leukocytes from 
histoincompatible donors or proliferating T cell clones did not induce T N F 
m R N A expression in monocytes. Bacterial, viral and mycoplasma contamin-
ations were excluded as causative agents. Sizing experiments on SDS con-
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F/g. /. TNF mRNA and IL-1 mRNA expression in monocytes stimulated by Jurkat 
cells (a) or by K562 (b). a RNA was prepared from monocytes cultured for 2 h in medium 
(lane 1); with 5 x 106 Jurkat cells (lane 2); with 5 x 106 UV-irradiated Jurkat cells (lane 3); 
from 5 x 106 viable Jurkat cells cultured for 2 h with UV-irradiated monocytes (lane 4), 
and from 5 x 106 Jurkat cells without monocytes (lane 5). The tumor cells were removed 
from all monocyte-containing cultures before RNA extraction. b RNA from monocytes 
cultured for 2 h in medium (lane 1); with Staphylococcus aureus 50 i^g/ml (lane 2); with 
5 x 106 K562 cells (lane 3); from 3 x 106 (lane 4), and 9 x 106 (lane 5) K562 cells without 
monocytes. The Northern blots were sequentially probed with TNF, IL-la, IL-lß and ß-
actin cDNA probes. 
taining Polyacrylamide gels and on H P L C using gel permeation chromato-
graphy revealed a Jurkat cell membrane fraction of about 40 kD with this 
monocyte-activating capacity. The biologically active membrane constituent 
was sensitive to periodate treatment and relatively resistant to treatment 
with protease and glutaraldehyde, thus pointing at a glycoprotein structure as 
the monocyte-activating agent. 
TNF Production during Tumor Growth in vivo 
T N F production has repeatedly been reported for tumor tissues from 
human biopsies [10, 11]. We also found T N F m R N A Signals by in situ 
hybridization and T N F protein stained by immunohistochemical staining in 
biopsies of colon and ovarian carcinomas. To systematically follow T N F 
synthesis in a murine tumor model, sections of fibrosarcoma biopsies from 
different stages of tumor growth were subjected to in situ hybridization with 
a T N F R N A probe and also staining with a polyclonal anti-rmTNF immuno-
Fig. 2. TNF mRNA expression in solid tumors during tumor growth. Tumor tissue 
(CFS-1) from day 8 (a, d), day 15 (b, e) and day 20 (e,f) after tumor implantation were 
hybridized with a TNF RNA probe. The photographs display the same tissue area x 250 as 
light (a-c) and dark (d-f) field, respectively. 
globulin. The number of cells positive for T N F mRNA (fig. 2) and for T N F 
protein (data not shown) increased during tumor growth. Also, in the 
fibrosarcoma tumor model and in a tumor model using the T cell tumor ESb, 
T N F mRNA was clearly present in spieen cells of tumor-bearing animals. 
Thus, although no circulating T N F was detected in the serum of these mice 
by ELISA and in the biological assay, T N F production in tumor and spieen 
became obvious with tumor growth. 
Function ofTNF in vivo 
In order to get some insight into the role of such tumor-induced 
endogenous T N F for tumor growth, animals were treated with neutralizing 
anti-murine T N F monoclonal antibodies. The animals had TNF-neutraliz-
ing antibody serum levels from the time of tumor cell implantation until the 
end of the experiment. No difference in size or weight of the primary 
fibrosarcoma tumor was found when the anti-TNF-treated animals were 
compared to untreated tumor-bearing mice. However, a significant effect of 
anti-TNF treatment became obvious when the numbers of metastases were 
compared in tumor models using metastasizing tumors. Metastases in livers 
and spleens of mice inoculated with ESb, a highly metastatic T cell tumor, 
and in lungs of mice inoculated with Lewis lung Carcinoma were counted. In 
both Systems fewer metastases were found in animals treated with anti-TNF 
antibodies. This indicated a supportive function of endogeneous T N F for the 
development of metastases from primary tumors. 
Discussion 
The results described above clearly demonstrate the capability of a 
tumor cell constituent to activate human monocytes as shown by the 
induction of mRNA for T N F and IL-1 and release of T N F protein. This 
could account for the enhanced serum levels of T N F found in tumor patients 
[6, 7] and for the cytostatic activity of monocytes from Cancer patients [8, 9]. 
It is not excluded that other cells besides monocytes could also be stimulated 
for T N F production. Possible candidates would be T cells, N K cells and 
granulocytes which all have been shown to be T N F producers [12-14]. 
The Observation that the K562 cells in contrast to Jurkat cells did not 
induce the release of 17 kD T N F from monocytes seems most likely to be due 
to absorption of this soluble T N F by the relatively numerous T N F receptors 
found on the K562 tumor cells [4]. Clearly, both tested tumor cell lines 
induced biosynthesis of T N F . Preliminary characterization of the possible 
candidate for the activating agent suggested a 40-kD glycoprotein con-
stitutent on the outer cell membrane of the tumor cells in the case of Jurkat 
cells. Experiments to further clarify the structure of this agent are ongoing. 
Even though there is conflicting evidence concerning the presence of 
T N F in serum from Cancer patients [6, 7, 15], production in tumor tissue has 
been reported by several groups [5, 6, 10, 11]. In one report, T N F was 
probably produced by the tumor cells [11] while in the others the host cells 
were the more likely producers. The results presented here confirm the 
finding of tumor-induced T N F production in vivo in two mouse tumor 
models. Cancer cachexia, anemia and hypercalcemia could possibly be 
induced by such endogenous T N F [16, 17]. It can also be assumed that such 
endogenous T N F interferes with tumor growth and dissemination. T N F 
exerts a number of biological effects that could be important in this respect, 
e.g. cytostatic or cytotoxic activity, induction of angiogenesis, enhanced 
expression of adhesion molecules, activation of monocytes/macrophages and 
granulocytes, enhanced expression of class I and II M H C antigen expression, 
and increased Plasminogen activator inhibitor activity [reviewed in 3, 18]. 
Depending on the tumor model under investigation, different sets of Parame-
ters could be involved in the outcome of the experiment. It is important to 
stress that with the multitude of T N F effects in mind it is not so surprising 
that in the complex sequence of events leading to metastasis the net effect of 
T N F seems to support formation of metastases. Reports from other investi-
gators support this notion that T N F enhances the metastatic potential of 
tumor cells [19-21]. It remains to be analyzed which stages of tumor growth 
and metastasis are influenced by T N F and whether one could make use of 
this influence for a patienfs benefit by application of T N F or T N F antago-
nists, respectively. 
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